ClinicalTrials.gg
TerminatedNCT00210561Updated Jun 10, 2011

A Study of the Effectiveness and Safety of Tramadol HCl/Acetaminophen Compared to Placebo in Treating Acute Low Back Pain

A Phase 4 interventional study of tramadol hydrochloride , acetaminophen in Back Pain and Low Back Pain, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Terminated. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-06-10.

Primary conditionLow Back PainRegistry: Back PainReclassifiedWhy we changed it
Registry
Back Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Low Back Pain
Why
  1. The study's listed conditions name Low Back Pain, a narrower term within Back Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Why this study was terminated
Study was stopped shortly after initiation due to change in strategic direction of the company; no safety concerns were observed that impacted this decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing acetaminophen in Low Back Pain — none open to participants now, none under way, none of them phase 3. Acetaminophen · Low Back Pain.

Enrollment
9th of 10
22 · median 120
Started
2005
the only one that year
Phase 4
5 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
1 of 10
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 10 studies testing acetaminophen in Low Back Pain, this one is the 9th largest by enrollment, is the only one that started in 2005, is one of 5 in phase 4, and was the 1st registered.

Low Back Pain

2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

None of the 10 studies testing acetaminophen in Low Back Pain is open now. The open studies under Low Back Pain, anywhere →

Where they have run

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing acetaminophen in Low Back Pain as a file.
02

Study summary

The purpose of this study is to explore the pain-relieving effects and safety of Tramadol HCl/acetaminophen as compared to placebo in patients experiencing acute low back pain. Tramadol HCl/acetaminophen is approved for short-term management of acute pain. The combination of tramadol HCl/acetaminophen has been shown to be effective for the treatment of acute musculoskeletal pain. Patients who experienced at least moderate acute low back pain for 2 to 10 days before study entry will be randomized to receive either tramadol HCl/acetaminophen or placebo.

Read the detailed description

Tramadol HCl/acetaminophen is approved for short-term (five days or less) management of acute pain. The combination of tramadol HCl/acetaminophen has been shown to be effective for the treatment of acute musculoskeletal pain. The current study is a multicenter, randomized, double-blind, placebo-controlled, parallel group study. Patients with acute low back pain for 2 to 10 days before study entry will be enrolled. At the screening visit, patients will complete questionnaires about their level of pain and disability. Patients will be randomized (like the toss of a coin) to receive either tramadol HCl/acetaminophen or placebo. Patients will take 2 tablets of study medication every 4 to 6 hours as needed for low back pain, but not more than 8 tablets per 24-hour period. Patients will call the Interactive Voice Response (IVR) system to complete a pain assessment prior to taking the first dose of study medication. Also starting on Day 1, patients will call the IVR system every night at bedtime for the remainder of the study, to complete assessments related to the following: low back pain and pain relief in the last 24 hours, current pain, pain interference with sleep and the number of study medication tablets and doses taken that day. The objective of this study is to compare the effectiveness and safety of tramadol HCl/acetaminophen versus placebo for the treatment of acute low back pain.

2 tramadol/acetaminophen 37.5/325 milligram oral tablets or 2 placebo tablets every 4 to 6 hours as needed for low back pain, but no more than 8 tablets per day, for 5 days, or until there is no further need for pain medication

03

Conditions studied

  • Back Pain
  • Low Back Pain

Browse trials for

Keywords

  • Pain
  • Acute Low Back Pain
  • Back
  • Lower back
04

In context

Low Back Pain Reclassified

2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

This study's enrollment of 22 is below the median of 60 across 2,368 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.

Compared within Low Back Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Back Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic with acute low back pain, with or without radiating pain no lower than the knee, for 2 to 10 days
  • Average acute low back pain score in the last 24 hours of >= 5 on an 11-point scale at Visit 1
  • In generally good health
  • If female of , using an acceptable method of

Exclusion criteria

Exclusion Criteria:

  • No use of ibuprofen, acetaminophen, or aspirin within 6 hours of the first dose of study medication
  • No use of any other prescription or over-the-counter medication for pain within 24 hours of the first dose of study medication
  • No use of medications for epilepsy or depression in the past 3 weeks
  • No use of within 3 months of study entry or any other long-term treatment with steroids
  • No use of of tramadol HCl, tramadol HCl/acetaminophen, or any other oral opioid or opioid combination during the course of the current episode of acute low back pain
  • No use of transcutaneous electrical nerve stimulation (TENS) unit within 2 weeks of study entry
  • No use of an drug in past 30 days
  • No use of botulinum toxin for the treatment of back pain within 3 months
  • No chronic continuous back pain or acute pain on top of chronic back pain
  • No acute low back pain associated with chills or fever
  • No pain below the knee
  • No neurological signs, such as muscle weakness
  • No risk of spinal infection
  • No worsening of pain when lying down
  • No history of significant medical conditions
  • No need for urgent evaluation of the spine by neuroimaging
  • No treatment during this episode by a chiropractor, physical therapy, massage, acupuncture, or Reiki treatments
  • No current litigation over back pain
  • No back pain related to a motor vehicle accident or work injury
  • No pain more painful than their low back pain
  • No progressive or degenerative neurological disorders
  • No kidney damage
  • Not pregnant or breast-feeding
  • No condition that might affect the way the body absorbs or processes the study drug
  • No bleeding condition
  • No history of suicidal ideas or suicide attempts in the past 2 years
  • No history of a major psychiatric disorder in past 6 months
  • No history of drug or alcohol abuse or dependence
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
22 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. Pain relief on Day 2 of treatment with study medication

Secondary outcomes

  1. Analgesic scores for the entire treatment period including: pain relief across all study days, Brief Pain Inventory, Roland and Morris Disability Questionnaire, Subject Global Impression of Change at final visit

08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 21, 2005
Start
Mar 2005
CompletionActual
Apr 2005
Last update
Jun 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00210561
Collaborators
PriCara, Unit of Ortho-McNeil, Inc.
First posted
Sep 21, 2005
Start date
Mar 2005
Completion
Apr 2005
Last update
Jun 10, 2011

Study contacts

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tramadol · Acetaminophen

Start the discussion